A landmark 2023 Science study found taurine levels decline with age and that supplementation extended healthspan and lifespan in mice and monkeys. Three years later, here's what has — and hasn't — been confirmed in humans.
Few single studies have driven as much sustained interest in one molecule as the June 2023 *Science* paper "Taurine deficiency as a driver of aging," led by researchers at Columbia University. It reported that circulating taurine levels decline substantially with age across mice, monkeys, and humans, and that restoring taurine through supplementation extended both lifespan and healthspan measures in mice and improved multiple markers of aging in middle-aged rhesus monkeys. Three years on, taurine supplementation has become a mainstay of many longevity stacks — but the human evidence base has grown more slowly than the hype.
The Columbia team, led by Vijay Yadav, measured taurine across species and found levels dropped by roughly 80% between young and old mice, and by about 40-80% between young adulthood and old age in cynomolgus monkeys and in a cross-sectional human dataset. In mice, taurine supplementation starting in middle age extended median lifespan by 10-12% and improved a wide panel of healthspan measures — bone density, muscle strength, glucose tolerance, and reduced markers of DNA damage and cellular senescence (the "zombie cells" discussed in senolytic research). In monkeys, taurine supplementation for six months improved markers of bone density, immune function, and body weight regulation.
This was a genuinely rigorous, multi-species study published in one of the most selective journals in science, which is why it generated so much legitimate scientific interest rather than just social media buzz.
Taurine is a sulfur-containing amino acid (technically an amino sulfonic acid) that the body both synthesizes and obtains from diet, concentrated in meat, fish, and shellfish. It is not incorporated into proteins the way other amino acids are; instead, it exists as a free molecule at very high concentrations in tissues with high metabolic demand — heart, skeletal muscle, retina, and brain.
Its proposed roles in aging biology include mitochondrial function support (taurine is required for proper mitochondrial tRNA modification, and taurine deficiency causes measurable mitochondrial dysfunction), antioxidant and anti-inflammatory effects, osmoregulation and calcium handling in cells, and bile acid conjugation in the liver.
This is where the taurine story becomes more complicated than the initial coverage suggested. The 2023 paper's human data was cross-sectional (taurine levels correlated with age and various health measures) — it did not include a human supplementation trial testing whether raising taurine levels improves human healthspan or lifespan outcomes. That trial has not yet been completed and published as of this writing.
Separately, taurine has decades of existing human safety and efficacy data in other contexts: it's a well-studied ingredient in energy drinks and sports nutrition (typically 1,000-2,000 mg per serving), has been studied for heart failure (multiple small trials suggest modest benefits on cardiac function at 1,500-3,000 mg/day), and has a long safety record at doses up to 3 g/day in clinical trials for unrelated conditions. What's missing is a trial testing taurine specifically for aging biomarkers or longevity outcomes in humans, at the doses and duration that would meaningfully test the hypothesis from the animal data.
A widely discussed 2023 correspondence in *Science* also raised a methodological question: whether human taurine levels actually decline with age as consistently as the mouse and monkey data suggested, given variability in existing human datasets. The original authors have defended their findings, and the debate reflects normal scientific discourse following a high-profile paper rather than a retraction or major flaw — but it is a reason for calibrated confidence rather than certainty.
The honest current position: taurine's mechanistic case and animal data are strong enough that testing supplementation is reasonable for people already comfortable adding evidence-informed, low-risk compounds to a longevity stack, but the "proven anti-aging molecule" framing seen in short-form video is ahead of where the human clinical evidence actually sits.
Doses discussed in longevity circles typically fall in the 1,000-3,000 mg/day range, informed by the safety data from cardiac and sports-nutrition research rather than a dose specifically validated for longevity outcomes in humans. Food sources — shellfish, dark meat poultry, fish — provide meaningfully smaller doses than supplemental taurine, so anyone targeting gram-level intake will need a supplement.
Taurine is a rare case of a viral supplement trend traceable to one specific, well-conducted, high-impact scientific paper rather than anecdote or marketing. That paper's multi-species lifespan and healthspan data is genuinely compelling. What has not yet happened is the human randomized controlled trial that would confirm the animal findings translate to people — a gap the original researchers themselves have acknowledged is the necessary next step. Taurine has a long safety track record at the doses being discussed, which lowers the bar for trying it, but "safe and mechanistically plausible" is a different claim than "proven to extend human lifespan," and the current evidence supports the former, not yet the latter.